BioWorld

March 30, 2005

View Archived Issues

TolerRx Raises $31M In Series D To Advance Diabetes Drug TRX4

Less than a year after withdrawing a proposed initial public offering, TolerRx Inc. dipped into the private markets, raising $31 million in a Series D round. (BioWorld Today) Read More

BioCurex Licenses Biomarker To Abbott In First Significant Deal

Read More

Unlike In Hollywood, Golden Rice Sequel Trumps Original

Read More

Syngenta Subject Of Inquiry Over Unapproved Corn Sales

Read More

Other News To Note

Read More

Appointments And Advancements

Read More